⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5617623 | 0.98 | HPGD (0.41) | — | |
| SCHEMBL332622 | 0.93 | DNM1 (0.44) | — | |
| SCHEMBL4587698 | 0.91 | DNM1 (0.48) | — | |
| SCHEMBL3506846 | 0.91 | DNM1 (0.48) | — | |
| SCHEMBL8168522 | 0.91 | DNM1 (0.48) | — | |
| SCHEMBL4588691 | 0.91 | DNM1 (0.48) | — | |
| Hydrochloric Acid SCHEMBL5618261 | 0.89 | DNM1 (0.50) | — | |
| SCHEMBL7048097 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL8665208 | 0.82 | — | — | |
| Oxalic Acid SCHEMBL5618292 | 0.82 | MAOB (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531181-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | Pharma Two B Ltd. (IL) | 2012-12-12 | — | — | EP | claimed |
| US-20120301542-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | PHARMA TWO B LTD. (IL) | 2012-11-29 | — | — | US | claimed |
| CN-102791258-A | Extended release formulations of rasagiline and uses thereof | PHARMA TWO B LTD | 2012-11-21 | — | — | CN | claimed |
| WO-2011095973-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | PHARMA TWO B LTD. (IL) | 2011-08-11 | — | — | WO | claimed |
| EP-1686973-A4 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RES & DEV FOUNDATION (IL) | 2009-03-25 | — | — | EP | claimed |
| EP-1942881-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL FAILURE | Technion Research and Development of Foundation, Ltd. (IL) | 2008-07-16 | — | — | EP | claimed |
| US-20080090915-A1 | METHOD FOR PREVENTING OR ATTENUATING ANTHRACYCLINE-INDUCED CARDIOTOXICITY | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2008-04-17 | — | — | US | claimed |
| WO-2007039909-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL FAILURE | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2007-04-12 | — | — | WO | claimed |
| US-20070082958-A1 | Methods for treatment of renal failure | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2007-04-12 | — | — | US | claimed |
| US-20060287401-A1 | Methods for treatment of cardiovascular disorders and diseases | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2006-12-21 | — | — | US | claimed |
| EP-1686973-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD. (IL) | 2006-08-09 | — | — | EP | claimed |
| US-20050171210-A1 | Compositions and methods for treatment of cardiovascular disorders and diseases | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2005-08-04 | — | — | US | claimed |
| WO-2005051371-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2005-06-09 | — | — | WO | claimed |
| EP-3517103-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | Pharma Two B Ltd. (IL) | 2019-07-31 | — | — | EP | disclosed |
| EP-2531181-B1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | PHARMA TWO B LTD (IL) | 2019-04-10 | — | — | EP | disclosed |
| US-10208017-B2 | Heterocycles capable of modulating T-cell responses, and methods of using same | NOGRA PHARMA LIMITED (IE) | 2019-02-19 | — | — | US | disclosed |
| US-6251950-B1 | ADMINISTERING TO THE PATIENT AN ALIPHATIC-PROPARGYLAMINE OR SALT FOR THE TREATMENT OF ACUTE AND CHRONIC DISEASES IN WHICH CELL DEATH OCCURS BY APOPTOSIS OR FOR THE TREATMENT OF PREMATURE DEGENERATION OF CELLS IN MAMMALS | UNIVERSITY OF SASKATCHEWAN (CA) | 2001-06-26 | — | — | US | disclosed |
| EP-0996612-A2 | ALIPHATIC PROPARGYLAMINES AS CELLULAR RESCUE AGENTS | University of Saskatchewan Technologies Inc. (CA) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999003817-A2 | ALIPHATIC PROPARGYLAMINES AS CELLULAR RESCUE AGENTS | UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES INC. (CA) | 1999-01-28 | — | — | WO | disclosed |
| US-5840979-A | USEFUL IN THE TREATMENT AND PREVENTION OF DISEASES IN WHICH CELL DEATH OCCURS BY APOPTOSIS | UNIVERSITY OF SASKATCHEWAN (CA) | 1998-11-24 | — | — | US | disclosed |